GT Medical Technologies Appoints James Leech as New Chief Financial and Strategy Officer

GT Medical Technologies Welcomes James Leech

GT Medical Technologies, a pioneering medical device company dedicated to enhancing the quality of life for patients affected by brain tumors, has recently appointed James Leech as its Chief Financial and Strategy Officer. This strategic move is expected to bolster the company's efforts in the commercialization of its innovative product, GammaTile®.

The Role of James Leech

James Leech brings over a decade of experience in the life sciences sector. His extensive background includes successful tenures leading commercial-stage healthcare companies both in advisory and operational roles. As he steps into this new position, Mr. Leech will focus on amplifying commercial opportunities for GammaTile, while also steering the company's overarching corporate strategy and managing financial and investor relations.

In the words of Per Langoe, CEO of GT Medical Technologies, “We are thrilled to have James on board. His diverse experience in financial and strategic management, particularly within the healthcare domain, opens up vast potentials for our continued growth and broader adoption of our technologies.”

About GammaTile

GammaTile represents a significant breakthrough in radiation therapy. This innovative product goes beyond traditional methods by facilitating immediate localized radiation at the tumor site during surgery. Such an approach considerably reduces the interval between surgery and treatment, maximizing the chances of effectively targeting residual cancer cells right when they are most vulnerable. Moreover, it aims to lower the risk of tumor recurrence, thus improving patient outcomes significantly.

Since its market launch in March 2020, GammaTile has gained traction and is now used in over 100 leading medical centers across the United States, further validating its effectiveness within both academic and community healthcare settings.

James Leech's Background

Before joining GT Medical Technologies, Mr. Leech held the position of Chief Financial and Strategy Officer at Moximed, a commercial-stage orthopedic device company. Additionally, he played a pivotal role as the Chief Business Officer at Palette Life Sciences, contributing significantly to the company's journey from its inception to its eventual acquisition by Teleflex, Inc. His career began in life science investment banking, which provided him with a strong foundation for maneuvering through complex financial landscapes.

Moreover, Mr. Leech's expertise spans across various segments of the life sciences industry, including MedTech, healthcare services, and biopharmaceuticals. His international experience includes engaging in transactions and operational initiatives involving companies in Europe and Asia-Pacific, giving him a nuanced perspective on global market dynamics.

Future Prospects

Reflecting on his new role, Mr. Leech expressed, “I am excited to join a team that is so committed to transforming the lives of patients grappling with brain tumors. GT Medical Technologies is well-positioned for substantial growth, and I am eager to collaborate with all stakeholders to continue expanding the reach and impact of GammaTile.”

As GT Medical Technologies continues its mission to fill the existing gaps in brain tumor treatment, the leadership of James Leech is expected to play a crucial role in navigating the next phase of growth, ensuring more patients and doctors have access to this innovative therapeutic solution.

For more information about GammaTile and GT Medical Technologies, visit their official website at gammatile.com and follow them on social media platforms like Facebook, Instagram, LinkedIn, and X.